Contact us

Call 612-863-8716.

800 E 28th St
Minneapolis, MN 55407

Research program leaders

Available studies

The following is a current list of our open, cancer-related research studies at Virginia Piper Cancer Institute locations, part of Allina Health. Patients can participate in the studies at the locations listed with each study.

Breast cancer

  • Seattle Genetics SGN-LIV2 Triple Negative Study
    • Description: Phase 1b/2 Study of SGN-LIV1A + pembrolizumab for first-line treatment of unresectable locally-advanced or metastatic triple negative breast cancer
    • Locations: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital
  •  Roche WO40181 HR+ Breast Cancer Study
    • Description: Phase II RCT of venetoclax + fulvestrant vs. fulvestrant in ER+, HER2 negative metastatic breast cancer after CDK4/6 inhibitor therapy
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital
  • Odonate ODO-TE-B301 HR+ Breast Cancer Study
    • Description: Phase 3 study of tesetaxel + reduced dose of capecitabine vs. capecitabine alone in HR+, HER2 negative, metastatic breast cancer previously treated with a taxane in (neo)adjuvant setting
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital
  • Coming soon: Polyphor POL6326-009 HER2-Neg Breast Cancer Study
    • Description: Phase 3 study of balixafortide + eribulin vs. eribulin alone for HER2 negative, metastatic breast cancer
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital
  • Immunogen IMMU-132-09 Breast Cancer Study
    • Description: Phase 3 study of sacituzumab govitecan vs. physician’s choice in HR+, HER2 neg metastatic breast cancer following 2 prior chemo regimens
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital
  • LAM 001-2018 ELITE Protocol (LAM is only looking for patients with active disease at this time.)
    • Description: Collection of blood from Healthy Patients, Patients with Benign Disease, and Patients with Cancer.
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital

Colorectal cancer

  • LAM 001-2018 ELITE Protocol (LAM is only looking for patients with active disease at this time.)
    • Description: Collection of blood from Healthy Patients, Patients with Benign Disease, and Patients with Cancer.
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital

Cholangiocarcinoma

  • No available trials at this time

Esophageal cancer

  • Takeda TAK-931-2001 Study
    • Description: Phase 2 study to evaluate TAK-931 single agent in pts with locally advanced or metastatic squamous esophageal cancer after first line tx formetastatic disease
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital

Gastric cancer

  • No available trials at this time

Glioblastoma

  • No available trials at this time

Gynecology cancers (cervical and ovarian cancer)

  • Epicentrix Quadruple Threat
    • Description: Randomized 2:1 study of RRx-001 + carboplatin rechallenge followed by maintenance RRx-001/carboplatin vs. standard care therapy for epithelial ovarian cancer, fallopian tube or primary peritoneal cancer or malignant mixed mullerian tumor (MMMT) following first line platinum therapy
    • Location: Abbott Northwestern Hospital

Head and neck cancer

  • Rakuten Aspyrian Recurrent Head & Neck Cancer Study
    • Description: Phase 3 randomized open-label study of ASP-1929 photoimmunotherapy vs.physician's choice SOC for locoregional, recurrent head & neck squamous cell carcinoma on or after at least 2 prior lines of therapy
    • Location: Abbott Northwestern Hospital

Hematology

  • No available trials at this time

Hepatobiliary cancer

  • Mayo Hepatobiliary Registry and Biorepository
    • Description: International registry of hepatobiliary cancers including hepatocellular carcinoma, cholangiocarcinoma, and gallbladder adenocarcinoma, and unaffected individuals
    • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus
  • LAM 001-2018 ELITE Protocol (LAM is only looking for patients with active disease at this time.)
    • Description: Collection of blood from Healthy Patients, Patients with Benign Disease, and Patients with Cancer.
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital

Lung cancer

  • Takeda TAK-931-2001 Study
    • Description: Phase 2 study to evaluate TAK-931 single agent in patients with locally advanced or metastatic squamous lung cancer after ≥ 2 lines of tx formetastatic disease
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital
  • Epicentrix Quadruple Threat  - Small Cell Lung Cancer 
    • Description: RCT of RRx-001 weekly x 6 followed by 6 cycles of platinum doublet, and maintenance RRX vs. RRx-001 weekly x 3 followed by platinum based chemotherapy + RRx-001 for up to 6 cycles and then RRX-001 maintenance
    • Location: Abbott Northwestern Hospital
  • Epicentrix Quadruple Threat - NSCLC 
    • Description: RCT of RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance vs. RRx-001 weekly until progression followed by up to 6 cycles of platinum doublet and then RRx-001 maintenance for patients with stable disease or better after platinum therapy
    • Location: Abbott Northwestern Hospital
  • AZ ADRIACTIC Limited Stage SCLC
    • Description: RCT of placebo-controlled consolidation treatment durvalumab or durvalumab and tremilimumab for patients with limited stage SCLC who have not progressed following concurrent chemoradiation therapy
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital

Lymphoma/Leukemia

  • Debiopharm 1562-201 NHL Study
    • Description: Phase 2 study of Debio 1562+ rituximab in relapsed/refractory DLBCL
    • Locations: Abbott Northwestern Hospital, Mercy Hospital
  • Trovagene TROV-052 AML Study
    • Description: Phase 1b/2 study of PCM-075 + low-dose cytarabine or decitabine in Acute Myeloid Leukemia
    • Locations: Abbott Northwestern Hospital
  • DeNovo DLBC Lymphoma DB102-02
    • Description: Phase 3 study ofenzastaurin + R-CHOP versus R-CHOP in treatment-naïve high-risk DLBC Lymphoma with genomic biomarker DGM1
    • Locations: Abbott Northwestern Hospital, Mercy Hospital
  • AZ Mantle Cell Lymphoma (MCL) SUMMIT Registry:
    • Description: Registry study of patients who are initiating a novel agent for MCL to assess treatment patterns, response rates, PFS, and overall survival.
    • Locations: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital

Melanoma

  • BMS CA209-8FC Metastatic Melanoma Study
    • Description: Phase 1 study to compare nivolumab drug product process D to nivolumab drug product process C in patients with Stage IIIa/b/c/d or Stage IV melanoma after complete resection
    • Location: Unity Hospital

Multiple myeloma

  • No available trials at this time.

Neuroendocrine cancer

  • Epicentrix Quadruple Threat - Neuroendocrine Tumors
    • Description: Single arm study of RRx-001 weekly until progression followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance for patients with stable disease or better at discontinuation of platinum
    • Location: Abbott Northwestern Hospital

Ovarian cancer

Pancreatic cancer

  • Geistlich GP-2250 1001 Pancreas Cancer Study
    • Description: Phase 1/ 2 trial of GP-2250 + gemcitabine in metastatic pancreatic cancer who have progressed on FOLFIRINOX
    • Locations: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital
  • University of Minnesota Tissue Procurement Study
    • Description: Development of Oncolytic Adenovirus targeting cancer stem cells: Tissue procurement study from pancreatic or esophageal cancer surgery (Kamath/Kelsey 863-8716)
    • Location: Abbott Northwestern Hospital
  • LAM 001-2018 ELITE Protocol (LAM is only looking for patients with active disease at this time.)
    • Description: Collection of blood from Healthy Patients, Patients with Benign Disease, and Patients with Cancer.
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital, United Hospital

Renal cell cancer

  • No available trials at this time

Solid tumor

  • No available trials at this time

Urothelial cancer

  •  EMD Serono MS201781-0031 Solid Tumor
    • Description: Phase 1b open label study of avelumab + M9241 (NHS-IL12) for patients who have progressed after ≥ 1 platinum regimen
    • Location: Abbott Northwestern Hospital, Mercy Hospital - Unity Campus, Mercy Hospital